Pembrolizumab (KEYTRUDA(R))
Sponsors
National Cancer Institute (NCI)
Conditions
Breast CancerEndocrine TumorsGastrointestinal/Genitourinary CancersMetastatic HPV-16 Positive Squamous Cell Anal CancerMultiple MyelomaNeuroendocrine TumorsNon-Small Cell Lung CancerOvarian Cancer
Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RecruitingNCT03412877
Start: 2018-09-06End: 2029-03-23Target: 285Updated: 2026-08-24
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
WithdrawnNCT04536922
Start: 2021-01-27End: 2021-01-27Updated: 2021-02-01